These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 28685495)
1. Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Jungnik A; Gansser D; Ebner T; Müller F Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):69-80. PubMed ID: 28685495 [TBL] [Abstract][Full Text] [Related]
3. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects. Choi H; Huang F; Flack M Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study. Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448 [TBL] [Abstract][Full Text] [Related]
6. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937 [TBL] [Abstract][Full Text] [Related]
7. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Katsube T; Miyazaki S; Narukawa Y; Hernandez-Illas M; Wajima T Eur J Clin Pharmacol; 2018 Jul; 74(7):931-938. PubMed ID: 29627897 [TBL] [Abstract][Full Text] [Related]
8. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Wiebe ST; Giessmann T; Hohl K; Schmidt-Gerets S; Hauel E; Jambrecina A; Bader K; Ishiguro N; Taub ME; Sharma A; Ebner T; Mikus G; Fromm MF; Müller F; Stopfer P Clin Pharmacokinet; 2020 Dec; 59(12):1627-1639. PubMed ID: 32504272 [TBL] [Abstract][Full Text] [Related]
9. Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects. Maekawa Y; Furuie H; Kato M; Myobatake Y; Kamiyama E; Watanabe A; Shiosakai K; Taguchi T; Bass R; Zhou J; Dishy V; Warren V; Vashi V; Ishizuka H Clin Drug Investig; 2019 Oct; 39(10):967-978. PubMed ID: 31321631 [TBL] [Abstract][Full Text] [Related]
10. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin. Sidharta PN; Dingemanse J Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633 [TBL] [Abstract][Full Text] [Related]
11. No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study. Otani N; Wakuda H; Imai H; Kuranari M; Ishii Y; Ito Y; Okubo A; Ogawa O; Takeda K; Ohyama T; Hasunuma T; Uemura N Clin Transl Sci; 2019 Sep; 12(5):513-518. PubMed ID: 31095880 [TBL] [Abstract][Full Text] [Related]
12. Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers. Gao L; Kaushik D; Ingalls K; Milner S; Smith N; Kong R Drugs R D; 2024 Sep; 24(3):477-487. PubMed ID: 39316278 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin. Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931 [TBL] [Abstract][Full Text] [Related]
14. Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects. Zhu T; Parker B; Wojtkowski T; Nishimura T; Garg JP; Han D; Fisniku O; Keirns J Clin Pharmacokinet; 2017 Jul; 56(7):747-757. PubMed ID: 27878567 [TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Jung JA; Lee SY; Kim JR; Ko JW; Jang SB; Nam SY; Huh W Drug Des Devel Ther; 2015; 9():745-52. PubMed ID: 25767372 [TBL] [Abstract][Full Text] [Related]
16. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail. Ebner T; Ishiguro N; Taub ME J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193 [TBL] [Abstract][Full Text] [Related]
17. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects. Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Min KL; Park MS; Jung J; Chang MJ; Kim CO Clin Ther; 2017 Sep; 39(9):1799-1810. PubMed ID: 28803122 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects. Huh KY; Kim E; Lee H; Jeon I; Suh H; Lee J; Lee Y; Yu KS; Lee S Clin Pharmacol Drug Dev; 2021 Feb; 10(2):207-213. PubMed ID: 32579298 [TBL] [Abstract][Full Text] [Related]
20. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]